Valuation: DiaMedica Therapeutics Inc.

Market Cap 501M 353M 309M 285M 267M 33.29B 511M 3.43B 1.33B 16.45B 1.33B 1.3B 57.06B P/E 2026 *
-7.89x
P/E 2027 * -7.44x
Enterprise Value 501M 353M 309M 285M 267M 33.29B 511M 3.43B 1.33B 16.45B 1.33B 1.3B 57.06B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.7%
Yield 2026 *
-
Yield 2027 * -
1 day+6.50%
1 week+11.97%
Current month+9.35%
1 month+7.38%
3 months-3.53%
6 months-20.41%
Current year-17.71%
1 week 5.77
Extreme 5.77
6.75
1 month 5.24
Extreme 5.245
6.75
Current year 5.24
Extreme 5.245
9.04
1 year 3.48
Extreme 3.475
10.42
3 years 1.94
Extreme 1.9382
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 31/12/2009
Director of Finance/CFO 60 31/03/2018
Chief Tech/Sci/R&D Officer 60 10/08/2025
Director TitleAgeSince
Director/Board Member 70 09/08/2010
Chairman 54 31/03/2008
Chairman 60 31/12/2024
Date Insider Type Main position Quantity % Market Cap.
05-31Option

Director

40,412 0.0750%
05-31Free

Chief Executive Officer

380,000 -
05-31Free

Director

40,412 -
Change 5-day change 1-year change 3-year change Capi.($)
+6.50%+11.97%+70.57%+54.12% 353M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.75%+5.50%+45.21%+122.09% 22.66B
Weighted average by Cap. +0.27%+5.14%+48.53%+122.57%

Financials

2026 *2027 *
Net sales - -
Net income -63.21M -44.55M -39.06M -36.01M -33.71M -4.2B -64.52M -433M -167M -2.08B -167M -164M -7.2B -78.02M -54.99M -48.22M -44.44M -41.61M -5.19B -79.64M -534M -207M -2.56B -206M -202M -8.89B
Net Debt - -
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
26/06/26 US$6.550 +6.50% 962,878
25/06/26 US$6.150 -3.30% 109,095
24/06/26 US$6.360 +1.27% 235,637
23/06/26 US$6.280 +6.62% 216,706
22/06/26 US$5.890 +0.68% 142,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.550USD
Average target price
15.50USD
Spread / Average Target
+136.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMAC Stock